DC4U’s GlycoDCTM Targeting Technology can be applied in the treatment of inflammatory diseases. This can be achieved via induction of regulatory T-cells by glycan-modification of disease specific antigens or peptides derives from these antigens.
We recently obtained strong evidence that certain glycans are involved in tolerance induction. Conjugation of these inhibitory glycans to specific antigens(as protein or peptide) instructs DCs to induce regulatory T-cells (Treg) and at the same time inhibit antigen specific effector T-cell generation. This tolerogenic feature is even maintained under inflammatory conditions. We foresee the potential application of this technology in the development of novel therapeutics for the treatment of inflammatory diseases.
Glycan conjugated disease specific antigens may effectively be used for the treatment of inflammatory diseases such as psoriasis, allergy, Alzheimer’s disease, Parkinson’s disease and transplantation. This will enable a whole new area of treatment for inflammatory diseases.
We do not have a research history is this application field. Therefore, we are looking for partners who are interested in co-development of the application for inflammation therapeutics.